COSCIENS Biopharma Statistics

Total Valuation

LON:0UGB has a market cap or net worth of GBP 7.80 million. The enterprise value is -1.13 million.

Market Cap	7.80M
Enterprise Value	-1.13M

Important Dates

The next estimated earnings date is Friday, August 8, 2025.

Earnings Date	Aug 8, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	1.79M
Shares Outstanding	n/a
Shares Change (YoY)	+57.27%
Shares Change (QoQ)	+0.13%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	2.89M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	1.12
PB Ratio	0.99
P/TBV Ratio	0.99
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.08
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.10

Financial Position

The company has a current ratio of 2.88, with a Debt / Equity ratio of 0.22.

Current Ratio	2.88
Quick Ratio	2.21
Debt / Equity	0.22
Debt / EBITDA	n/a
Debt / FCF	-0.15
Interest Coverage	-86.36

Financial Efficiency

Return on equity (ROE) is -151.97% and return on invested capital (ROIC) is -57.41%.

Return on Equity (ROE)	-151.97%
Return on Assets (ROA)	-23.33%
Return on Invested Capital (ROIC)	-57.41%
Return on Capital Employed (ROCE)	-48.77%
Revenue Per Employee	174,728
Profits Per Employee	-339,840
Employee Count	40
Asset Turnover	0.29
Inventory Turnover	3.78

Taxes

In the past 12 months, LON:0UGB has paid 383,899 in taxes.

Income Tax	383,899
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -97.91% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-97.91%
50-Day Moving Average	n/a
200-Day Moving Average	n/a
Relative Strength Index (RSI)	42.16
Average Volume (20 Days)	209

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, LON:0UGB had revenue of GBP 6.99 million and -13.59 million in losses. Loss per share was -4.68.

Revenue	6.99M
Gross Profit	3.30M
Operating Income	-9.09M
Pretax Income	-13.21M
Net Income	-13.59M
EBITDA	-8.14M
EBIT	-9.09M
Loss Per Share	-4.68

Full Income Statement

Balance Sheet

The company has 10.65 million in cash and 1.72 million in debt, giving a net cash position of 8.93 million.

Cash & Cash Equivalents	10.65M
Total Debt	1.72M
Net Cash	8.93M
Net Cash Per Share	n/a
Equity (Book Value)	7.85M
Book Value Per Share	2.50
Working Capital	10.29M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -10.89 million and capital expenditures -938,076, giving a free cash flow of -11.83 million.

Operating Cash Flow	-10.89M
Capital Expenditures	-938,076
Free Cash Flow	-11.83M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 47.26%, with operating and profit margins of -130.07% and -194.50%.

Gross Margin	47.26%
Operating Margin	-130.07%
Pretax Margin	-189.00%
Profit Margin	-194.50%
EBITDA Margin	-116.45%
EBIT Margin	-130.07%
FCF Margin	n/a

Dividends & Yields

LON:0UGB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-57.27%
Shareholder Yield	n/a
Earnings Yield	-174.25%
FCF Yield	-151.60%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on July 21, 2022. It was a reverse split with a ratio of 0.04.

Last Split Date	Jul 21, 2022
Split Type	Reverse
Split Ratio	0.04

Scores

LON:0UGB has an Altman Z-Score of -0.78 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.78
Piotroski F-Score	3